<DOC>
	<DOCNO>NCT02334982</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability profile TAK-137 administer single dose tablet escalate dose level healthy participant .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Escalating Single Doses TAK-137 Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-137 . TAK-137 test find safe well-tolerated dose . This study look safety ( lab result side effect ) pharmacokinetic property ( drug absorption , distribution , metabolism , excretion ) people take TAK-137 . This study design single ascend 6 Cohort dose study plan dos 2 , 5 , 15 , 50 , 100 mg Cohort 6 dose determine maximum tolerate dose ( MTD ) reach . Anticipated enrollment 48 . This study enrol 47 participant consist 6 Cohorts . Participants Cohorts 1 , 2 , 3 , 5 6 randomized receive single dose TAK-137 placebo 10-hour fast . Participants Cohort 4 randomize receive single dose TAK-137 placebo fast condition , follow single dose TAK-137 placebo feed condition 14 day later . Participants cohort 4 receive dose fast fed condition . The start dose 2 mg follow administration 5 , 10 , 0.5 20 mg . This single-center trial conduct United States . For Cohorts 1 , 2 , 3 , 5 , 6 overall time participate study 42 day . Participants make 4 visit clinic include one 5-day period confinement clinic , contact telephone 14 day last dose study drug follow-up assessment . For Cohort 4 overall time participate study 56 day . Participants make 7 visit clinic include two 5-day period confinement clinic , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<criteria>1 . Is healthy male nonpregnant , nonlactating female adult 18 55 year age inclusive time inform consent first study medication dose . 2 . Weighs least 45 kg body mass index ( BMI ) 18 30.0 kg/m^2 , inclusive Screening . 3 . Is able comply protocol willing sign inform consent prior undergoing studyrelated procedure . 1 . Has know hypersensitivity component formulation TAK137 . 2 . Has medical condition mental retardation cause cognitive impairment . 3 . Has risk suicide accord Investigator 's clinical judgment ( eg , per ColumbiaSuicide Severity Rating Scale [ CSSRS ] make suicide attempt previous 6 month ) . 4 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . 5 . There find participant 's medical history , physical examination , safety laboratory test ( include safety electroencephalogram [ EEG ] ) give reasonable suspicion disease would contraindicate take TAK137 , similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 6 . Has take exclude medication , supplement , food product list Excluded Medications Dietary Products table .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>